Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome

Open access
Magnasco, Alberto, Ravani, Pietro, Edefonti, Alberto, Murer, Luisa, Ghio, Luciana, Belingheri, Mirco, Benetti, Elisa, Murtas, Corrado, Messina, Giovanni, Massella, Laura, Porcellini, Maria Gabriella, Montagna, Michela, Regazzi, Mario, Scolari, Francesco, Ghiggeri, Gian Marco · 2012 · Journal of the American Society of Nephrology

Abstract

Idiopathic nephrotic syndrome resistant to standard treatments remains a therapeutic dilemma in pediatric nephrology. To test whether the anti-CD20 monoclonal antibody rituximab may benefit these patients, we conducted an open-label, randomized, controlled trial in 31 children with idiopathic nephrotic syndrome unresponsive to the combination of calcineurin inhibitors and prednisone. All children continued prednisone and calcineurin inhibitors at the doses prescribed before enrollment, and one treatment group received two doses of rituximab (375 mg/m(2) intravenously) as add-on therapy. The mean age was 8 years (range, 2-16 years). Rituximab did not reduce proteinuria at 3 months (change, -12% [95% confidence interval, -73% to 110%]; P=0.77 in analysis of covariance model adjusted for baseline proteinuria). Additional adjustment for previous remission and interaction terms (treatment by baseline proteinuria and treatment by previous remission) did not change the results. In conclusion, these data do not support the addition of rituximab to prednisone and calcineurin inhibitors in children with resistant idiopathic nephrotic syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2011080775

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 174

Metadata

Authors
Magnasco, A., Ravani, P., Edefonti, A., Murer, L., Ghio, L., Belingheri, M., Benetti, E., Murtas, C., Messina, G., Massella, L., Porcellini, M. G., Montagna, M., Regazzi, M., Scolari, F., & Ghiggeri, G. M.
Venue
Journal of the American Society of Nephrology
Published
2012-06
Volume
23
Issue
6
Pages
1117-1124
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2110192851
Cited by
174
References
2
FWCI
12.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome. https://app.cochat.ai/papers/10.1681/asn.2011080775
The paper
Magnasco, A., Ravani, P., Edefonti, A., Murer, L., Ghio, L., Belingheri, M., Benetti, E., Murtas, C., Messina, G., Massella, L., Porcellini, M. G., Montagna, M., Regazzi, M., Scolari, F., & Ghiggeri, G. M. (2012). Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2011080775

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.